Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Adler

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Nature Clinical Practice. Endocrinology & Metabolism|October 18, 2007
Patients with diabetes--to whom should one offer statin treatment?Amanda Adler
Nature Food|November 28, 2023
Live to eat and eat to live longerAmanda Adler, Rhea Saksena
Endocrinology, Diabetes & Metabolism Case Reports|March 15, 2019
Fatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patientYael Lefkovits, Amanda Adler
Applied Health Economics and Health Policy|May 8, 2020
Impact of a Global Pandemic on Health Technology AssessmentPaula K Lorgelly, Amanda Adler
The Lancet. Oncology|May 20, 2019
NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancerAdam Brooke, Ahmed Elsada, Amanda Adler
Pharmacoeconomics - Open|July 2, 2025
Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance ValueNeil Hawkins, Adrian Towse, Amanda Adler
BMJ Open|August 1, 2019
In primary care, is measuring free-thyroxine plus thyroid-stimulating hormone to detect hypopituitarism cost-effective? A cost utility analysis using Markov chain modelsBrian Shine, Tim James, Amanda Adler
Lancet (London, England)|March 21, 2006
Renoprotective effects of renin-angiotensin-system inhibitorsAmanda Adler, Irene Stratton, Brian Shine
The Lancet. Infectious Diseases|October 29, 2022
New ways of evaluating and purchasing antimicrobialsAmanda Adler, Sophie Cooper, Nick Crabb, et al.
The Lancet. Oncology|March 4, 2015
NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancerRosemary Lovett, Elisabeth George, Amanda Adler
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Nature Clinical Practice. Endocrinology & Metabolism|October 18, 2007
Patients with diabetes--to whom should one offer statin treatment?Amanda Adler
Nature Food|November 28, 2023
Live to eat and eat to live longerAmanda Adler, Rhea Saksena
Endocrinology, Diabetes & Metabolism Case Reports|March 15, 2019
Fatal squamous cell carcinoma from necrobiosis lipoidica diabeticorum in a diabetic patientYael Lefkovits, Amanda Adler
Applied Health Economics and Health Policy|May 8, 2020
Impact of a Global Pandemic on Health Technology AssessmentPaula K Lorgelly, Amanda Adler
The Lancet. Oncology|May 20, 2019
NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancerAdam Brooke, Ahmed Elsada, Amanda Adler
Pharmacoeconomics - Open|July 2, 2025
Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance ValueNeil Hawkins, Adrian Towse, Amanda Adler
BMJ Open|August 1, 2019
In primary care, is measuring free-thyroxine plus thyroid-stimulating hormone to detect hypopituitarism cost-effective? A cost utility analysis using Markov chain modelsBrian Shine, Tim James, Amanda Adler
Lancet (London, England)|March 21, 2006
Renoprotective effects of renin-angiotensin-system inhibitorsAmanda Adler, Irene Stratton, Brian Shine
The Lancet. Infectious Diseases|October 29, 2022
New ways of evaluating and purchasing antimicrobialsAmanda Adler, Sophie Cooper, Nick Crabb, et al.
The Lancet. Oncology|March 4, 2015
NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancerRosemary Lovett, Elisabeth George, Amanda Adler
Pageof 8